Nucleic Acid Therapeutics CDMO Market - Global Forecast 2025-2032

The nucleic acid therapeutics CDMO market is reshaping contract biopharma services, playing an integral role in supporting next-generation therapies. Senior decision-makers benefit from a clear understanding of partnership models, evolving technologies, and the competitive factors influencing global expansion in this rapidly progressing sector.

Market Snapshot of the Nucleic Acid Therapeutics CDMO Market

The Nucleic Acid Therapeutics CDMO Market is demonstrating sustained growth, having expanded from USD 10.77 billion in 2024 to USD 12.00 billion in 2025. A compound annual growth rate (CAGR) of 11.71% is projected, positioning the market to reach USD 26.14 billion by 2032. This momentum is being driven by significant capital inflows, strategic shifts in global supply chains, and heightened demand for both DNA and RNA therapeutic solutions from biopharma innovators. Industry resilience stems from technological advancements, proactive supply chain management, and a surge in new therapy modalities.

Scope & Segmentation of the Nucleic Acid Therapeutics CDMO Market

This report delivers a detailed analysis of the nucleic acid therapeutics CDMO sector, encompassing all principal business dimensions and highlighting where value is created for stakeholders. The segmentation framework encompasses critical facets and region-specific market influences.

• Therapeutics Type: DNA therapeutics and RNA therapeutics, each presenting specific manufacturing, regulatory, and delivery demands within their development pipelines.
• Service Type: Analytical testing and quality control, manufacturing, packaging and distribution, as well as process development and optimization, ensuring product safety and scalability.
• Therapeutic Applications: Genetic disorders, infectious diseases, neurological disorders, oncology, and rare disorders, showing a wide spectrum of target indications for nucleic acid-based therapies.
• End User: Academic and research institutes, biotechnology firms, and pharmaceutical companies, whose requirements shape CDMO service offerings and innovation priorities.
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East, Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan), each with distinct regulatory, supply chain, and infrastructure characteristics.
• Companies Covered: AGC Biologics Inc., Agilent Technologies, Inc., Ajinomoto Bio-Pharma Services, Almac Group Ltd., Biomay AG, BioSpring GmbH, Catalent, Inc., Charles River Laboratories International, Inc., CordenPharma International GmbH, Creative Biogene, Danaher Corporation, Eurofins Scientific SE, Evonik Industries AG, GenScript Biotech Corporation, Lonza Group Ltd., Polypeptide Group AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, The Scripps Research Institute, Touchlight Group, Univercells Group, WuXi AppTec Co., Ltd., reflecting a diverse and competitive global landscape.

Key Takeaways for Senior Decision-Makers

• Specialized CDMOs are vital in advancing genetic and RNA-based therapeutics from initial research to clinical and commercial production, ensuring regulatory alignment and rapid scalability.
• Emergent technologies—such as microfluidic encapsulation, digital process analytics, and modular manufacturing systems—support increased process efficiency and manufacturing flexibility across the nucleic acid therapeutics CDMO market.
• Integration of advanced data analytics and machine learning is informing process optimization, predictive maintenance, and providing greater transparency for operational oversight in contract manufacturing workflows.
• Segment-specific approaches are necessary, as each therapy type and application involves unique regulatory requirements, process development complexities, and distribution logistics.
• Regional focus varies by market, with the Americas emphasizing supply chain durability, EMEA leveraging collaborative regulatory strategies, and Asia-Pacific prioritizing cost-optimization and infrastructure advancement.
• Strategic partnerships with technology and raw material suppliers are increasingly critical to maintain supply chain robustness and service adaptability, particularly when navigating volatile global sourcing and trade conditions.

Tariff Impact on Supply Chains and Operational Models

Recent shifts in United States tariff policies affecting essential raw materials and reagents have led CDMO providers to broaden sourcing options and restructure procurement strategies. Elevated tariffs on specialty chemicals require companies to implement dual-sourcing methods, invest in localized warehousing, and strengthen domestic production capabilities. These actions, along with entering into long-term supplier contracts, have become fundamental for managing cost volatility and safeguarding continuity of manufacturing operations. Collaborating with chemical producers in shared locations and engaging in risk-sharing agreements help further optimize tariff exposure and supply reliability throughout the value chain.

Methodology & Data Sources

This report employs an integrated research design, combining secondary analysis of scientific publications and regulatory documents with direct interviews from sector leaders and technical specialists. A rigorous process involving data triangulation, scenario modeling, SWOT analysis, and repeat data validation is used to ensure the reliability and accuracy of all findings.

Why This Report Matters

• Provides executives with a structured approach to assessing prospective CDMO partners based on operational expertise, compliance record, and potential for technology-driven evolution.
• Clarifies changes in global supply chain models, preparing leadership teams to anticipate and respond to sourcing or tariff disturbances.
• Delivers targeted insight on technology adoption and process trends, empowering organizations to remain aligned with advancing industry standards and shifting client needs.

Conclusion

This report offers actionable intelligence for those leading investment, partnership, or operational strategy in nucleic acid therapeutics. It supports informed decision-making that aligns with evolving technology, market dynamics, and long-term sector opportunities.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.